Marc Cluzel, head of research at French drugmaker Sanofi-Aventis, talks to Reuters’ Ben Hirschler about the outlook for the company’s pipeline of new drugs.
The group had a major setback last June when U.S. experts recommended against approving its weight-loss drug Acomplia, also known as Zimulti, because of worries it might give some patients suicidal thoughts.But Cluzel says there are other exciting drugs in development, with half a dozen new products set to be submitted to regulators for approval this year.
The company has been stepping up its deals with biotech recently, clinching a major tie-up with Regeneron and signing a cancer vaccine deal with Oxford BioMedica that some analysts believe might eventually lead to a takeover.
Trackback
